<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05095467</url>
  </required_header>
  <id_info>
    <org_study_id>B2021-574</org_study_id>
    <nct_id>NCT05095467</nct_id>
  </id_info>
  <brief_title>HIPEC-AS in Patients With Peritoneal Metastasis of the Stomach or Esophagogastric Junction</brief_title>
  <official_title>Prospective Study With HIPEC-AS in Patients With Locally Advanced, Limited or Extensive Peritoneal Metastatic Adenocarcinoma of the Stomach or Esophagogastric Junction</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Xuefei.Wang</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shanghai Zhongshan Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      HIPEC-AS01 is an open, prospective, single-center phase II clinical study, which will include&#xD;
      &quot;cT4aNxM0, P0 or cTxNxM1, P1&quot; patients with gastric or esophagogastric junction&#xD;
      adenocarcinoma, to evaluate the efficacy and safety of systemic chemotherapy with HIPEC&#xD;
      combined with AS in the perioperative period. Patients enrolled will be divided into three&#xD;
      groups. Among them, group A is the patients with locally resectable GC; group B is patients&#xD;
      with peritoneal metastasis stage P1a or P1b, group C is patients with peritoneal metastasis&#xD;
      stage P1c. The primary purpose is to evaluate the 3-year overall survival rate.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      HIPEC-AS01 is an open, prospective, single-center phase II clinical study, which will include&#xD;
      Patients With cT4aNxM0, P0, or cTxNxM1*, P1 Adenocarcinoma of the Stomach or Esophagogastric&#xD;
      Junction, to evaluate the efficacy and safety of systemic chemotherapy with HIPEC combined&#xD;
      with AS in the perioperative period.&#xD;
&#xD;
      Patients enrolled will be divided into three groups. Among them, group A is the patients with&#xD;
      locally resectable GC; group B is patients with peritoneal metastasis stage P1a or P1b, group&#xD;
      C is patients with peritoneal metastasis stage P1c.&#xD;
&#xD;
      Intervention:&#xD;
&#xD;
      Group A: 1 cycle HIPEC+S-1 chemotherapy, sequential 3 cycles of chemotherapy (AS plan, Q21d ×&#xD;
      3), surgery+HIPEC, sequential 3 cycles of chemotherapy ( AS plan, Q21d × 3).&#xD;
&#xD;
      Group B: 1 cycle HIPEC+S-1 chemotherapy, sequential 3 cycles of chemotherapy (AS plan, Q21d ×&#xD;
      3), surgery+HIPEC, sequential 3 cycles of chemotherapy ( AS plan, Q21d × 3).&#xD;
&#xD;
      Group C: 1 cycle HIPEC+S-1 chemotherapy, sequential 3 cycles of chemotherapy (AS plan, Q21d ×&#xD;
      3), HIPEC+S-1 chemotherapy, sequential 3 cycles of chemotherapy ( AS plan, Q21d × 3).&#xD;
&#xD;
      In this study, the patient's overall survival was the main evaluation index. It is estimated&#xD;
      that the case recruitment will be completed in 2 years, and the follow-up time will be 3&#xD;
      years. The total sample size is approximately 157 cases.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 2021</start_date>
  <completion_date type="Anticipated">October 2026</completion_date>
  <primary_completion_date type="Anticipated">October 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>3-year Overall Survival, OS</measure>
    <time_frame>3 years</time_frame>
    <description>The time from the date of enrollment of the patient to the date of death or the date of the last follow-up</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>3-year Progression Free Survival, PFS</measure>
    <time_frame>3 years</time_frame>
    <description>The time from the date of enrollment of the patient to the first occurrence of disease progression or death from any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>NCI CTC Adverse Events Version 4.0</measure>
    <time_frame>1 year</time_frame>
    <description>Safety of HIPEC-AS plan</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">157</enrollment>
  <condition>Stomach Neoplasms</condition>
  <condition>Peritoneal Metastases</condition>
  <arm_group>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>patients with locally resectable GC (cT4aNxM0, P0)&#xD;
1 cycle HIPEC+S-1 chemotherapy, sequential 3 cycles of chemotherapy (AS plan, Q21d × 3), surgery+HIPEC, sequential 3 cycles of chemotherapy ( AS plan, Q21d × 3)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>patients with peritoneal metastasis stage P1a or P1b (cTxNxM1, P1a or P1b)&#xD;
1 cycle HIPEC+S-1 chemotherapy, sequential 3 cycles of chemotherapy (AS plan, Q21d × 3), surgery+HIPEC, sequential 3 cycles of chemotherapy ( AS plan, Q21d × 3)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>group C is patients with peritoneal metastasis stage P1c (cTxNxM1, P1c)&#xD;
1 cycle HIPEC+S-1 chemotherapy, sequential 3 cycles of chemotherapy (AS plan, Q21d × 3), HIPEC+S-1 chemotherapy, sequential 3 cycles of chemotherapy ( AS plan, Q21d × 3)</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>HIPEC</intervention_name>
    <description>The abdominal cavity will be filled with paclitaxel 120mg/m2 heated at 43℃ for 1 hour with a hyperthermic circulation machine.</description>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_label>Group B</arm_group_label>
    <arm_group_label>Group C</arm_group_label>
    <other_name>Paclitaxel injection</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paclitaxel-albumin</intervention_name>
    <description>albumin paclitaxel D1, D8; S-1: D1-D14</description>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_label>Group B</arm_group_label>
    <arm_group_label>Group C</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tegafur-gimeracil-oteracil potassium</intervention_name>
    <description>40mg bid(BSA&lt;1.5 m2) ，60mg bid(BSA&gt;=1.5 m2); D1-D14, po, bid.</description>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_label>Group B</arm_group_label>
    <arm_group_label>Group C</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Surgery+HIPEC</intervention_name>
    <description>gastrectomy with D2 lymphadenectomy+HIPEC procedure</description>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_label>Group B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. 18 years old ≤ age ≤ 75 years old;&#xD;
&#xD;
          2. The primary gastric lesion was diagnosed as gastric or esophagogastric junction&#xD;
             adenocarcinoma (papillary adenocarcinoma, tubular adenocarcinoma, mucinous&#xD;
             adenocarcinoma, signet ring cell carcinoma, and poorly differentiated adenocarcinoma.&#xD;
             )&#xD;
&#xD;
          3. The tumor is located in the stomach or esophagogastric junction (Siewert type II/III)&#xD;
&#xD;
          4. The preoperative clinical staging is cT4aNxM0, P0 or cTxNxM1*, P1 (*no other distant&#xD;
             metastases except peritoneal metastasis)&#xD;
&#xD;
          5. Good bone marrow reserve function: HB≥90g/L; ANC ≥1.5×10*9/L; PLT ≥80×10*9/L&#xD;
&#xD;
          6. Good liver and kidney function reserve: BIL ≤ 1.5 times the upper limit of normal&#xD;
             (ULN); ALT and AST ≤ 2.5×ULN; Crea≤1×ULN;&#xD;
&#xD;
          7. Good coagulation function: International normalized ratio (INR) or prothrombin time&#xD;
             (PT) ≤ 1.5 times ULN, activated partial thromboplastin time (APTT) ≤ 1.5 times ULN&#xD;
&#xD;
          8. ECOG (Eastern Cooperative Oncology Group) physical status score 0-2;&#xD;
&#xD;
          9. No prior treatment of chemotherapy, radiotherapy, targeted therapy, immunotherapy,&#xD;
             etc;&#xD;
&#xD;
         10. Written informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. There are distant metastases other than peritoneal metastases;&#xD;
&#xD;
          2. Complications of gastric cancer require emergency treatment, such as bleeding,&#xD;
             perforation, obstruction, etc.;&#xD;
&#xD;
          3. Suffer from other malignant tumors within five years;&#xD;
&#xD;
          4. Body temperature ≥38℃ or complicated with infectious diseases requiring systemic&#xD;
             treatment;&#xD;
&#xD;
          5. If there is a history of uncontrolled epilepsy, central nervous system disease, or&#xD;
             mental disorder, the investigator will determine whether the clinical severity hinders&#xD;
             the signing of informed consent or affects the patient's compliance with oral&#xD;
             medications;&#xD;
&#xD;
          6. Clinically serious (ie active) heart disease, such as symptomatic coronary heart&#xD;
             disease, New York Heart Association (NYHA) grade II or more severe congestive heart&#xD;
             failure, or severe arrhythmia requiring drug intervention, or recent history of&#xD;
             myocardial infarction within 12 months;&#xD;
&#xD;
          7. Severe respiratory diseases;&#xD;
&#xD;
          8. Severe liver and kidney dysfunction;&#xD;
&#xD;
          9. Upper gastrointestinal obstruction or abnormal physiological function or malabsorption&#xD;
             syndrome, which may affect the absorption of oral drugs;&#xD;
&#xD;
         10. Diseases such as severe diabetes, hyperthyroidism and hypothyroidism have not been&#xD;
             clinically controlled.&#xD;
&#xD;
         11. Those who continue to use glucocorticoid therapy within 1 month (except for local&#xD;
             application) or who require immunosuppressive therapy for organ transplantation;&#xD;
&#xD;
         12. Pregnant or lactating women;&#xD;
&#xD;
         13. The patient has participated or is participating in other clinical studies (within 6&#xD;
             months);&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Xuefei Wang, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fudan University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Xuefei Wang, MD</last_name>
    <phone>+86 13917270428</phone>
    <email>wang.xuefei@zs-hospital.sh.cn</email>
  </overall_contact>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>October 25, 2021</study_first_submitted>
  <study_first_submitted_qc>October 26, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 27, 2021</study_first_posted>
  <last_update_submitted>October 26, 2021</last_update_submitted>
  <last_update_submitted_qc>October 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 27, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Shanghai Zhongshan Hospital</investigator_affiliation>
    <investigator_full_name>Xuefei.Wang</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Stomach Neoplasms</keyword>
  <keyword>Peritoneal Metastases</keyword>
  <keyword>Hyperthermic Intraperitoneal Chemotherapy</keyword>
  <keyword>paclitaxel</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasm Metastasis</mesh_term>
    <mesh_term>Stomach Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
    <mesh_term>Tegafur</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

